Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARC151
- Development stage
- Preclinical
- Lead developer
- Third Arc Bio
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
ARC151 is a preclinical T-cell engager developed by Third Arc Bio, Inc. It is designed to co-stimulate the T-cell surface glycoproteins CD3 and CD28, aiming to activate the immune system's anti-cancer response. This dual targeting strategy is intended to facilitate a strong anti-cancer immune response while potentially minimizing side effects. The drug's development leverages Adagene's SAFEbody technology, a precision antibody masking platform, to selectively activate the drug's action in the tumor microenvironment. ARC151 is being investigated for the treatment of solid tumors.
02
Targets
CD28 (Cluster of Differentiation 28)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on ARC151.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARC151.